CUREVAC
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CUREVAC
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Contact:
+49707198830
Total Funding:
1.85 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2019-06-01
Board_member
Board_member
Board_member
Current Employees Featured
Franz-Werner Haas Chief Corporate Officer @ CureVac
Chief Corporate Officer
2012-01-01
Florian von der Mulbe Co-Founder, CPO @ CureVac
Co-Founder, CPO
2018-01-01
Ulrike Gnad-Vogt Chief Medical Officer @ CureVac
Chief Medical Officer
2013-08-01
Nigel Horscroft Area Head - Molecular Therapy @ CureVac
Area Head - Molecular Therapy
2017-01-01
Mariola Fotin-Mleczek Chief Technology Officer @ CureVac
Chief Technology Officer
2018-10-01
George Siber Member of SAB @ CureVac
Member of SAB
2015-01-01
Patrick Baumhof Vice President Formulation & Delivery @ CureVac
Vice President Formulation & Delivery
2017-01-01
Pierre Kemula CFO @ CureVac
CFO
2016-10-01
Steve Pascolo Co-Founder and CSO @ CureVac
Co-Founder and CSO
2000-05-01
Regina Heidenreich Head of Immunotherapy @ CureVac
Head of Immunotherapy
2012-12-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-08 | Frame Cancer Therapeutics | Frame Cancer Therapeutics acquired by CureVac | 32 M EUR |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CureVac
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - CureVac
GlaxoSmithKline
GlaxoSmithKline investment in Corporate Round - CureVac
European Investment Bank
European Investment Bank investment in Debt Financing - CureVac
KfW
KfW investment in Venture Round - CureVac
LBBW Asset Management
LBBW Asset Management investment in Series F - CureVac
Baden-Württembergische Versorgungsanstalt für Ärzte
Baden-Württembergische Versorgungsanstalt für Ärzte investment in Series F - CureVac
Landeskreditbank Baden-Württemberg
Landeskreditbank Baden-Württemberg investment in Series F - CureVac
Baillie Gifford
Baillie Gifford investment in Series F - CureVac
Chartwave
Chartwave investment in Series F - CureVac
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-04 | Curevac names Franz-Werner Haas as CEO |
Official Site Inspections
http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "CureVac"
CureVac - Wikipedia
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates …See details»
CureVac - Revolutionizing mRNA for life.
Jun 24, 2024 CureVac is a global biopharmaceutical company with more than 20 years of experience in developing the mRNA technology for medical purposes.See details»
CureVac - Wir revolutionieren die mRNA für das Leben …
CureVac ist ein globales biopharmazeutisches Unternehmen mit über 20 Jahren Erfahrung in der Entwicklung der mRNA-Technologie für medizinische Zwecke.See details»
CureVac - Crunchbase Company Profile & Funding
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.See details»
CureVac - AnnualReports.com
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In …See details»
CureVac - LinkedIn
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In …See details»
CureVac - Org Chart, Teams, Culture & Jobs | The Org
View CureVac's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CureVac - Simple English Wikipedia, the free encyclopedia
CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany. The company was …See details»
☑️CureVac — Consulting Organization from Germany
CureVac — Consulting Organization from Germany with 1001-5000 employees, has experience with European Commission Directorate-General for International Partnerships (EuropeAid …See details»
CureVac Receives Positive Validity Decision from European Patent …
Mar 27, 2025 European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A …See details»
CureVac Initiates Strategic Restructuring to Align Resources with …
Jul 3, 2024 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid …See details»
CureVac Company Profile - Office Locations, Competitors ... - Craft
CureVac has 5 employees across 6 locations and €53.76 m in annual revenue in FY 2023. See insights on CureVac including office locations, competitors, revenue, financials, executives, …See details»
CureVac Initiates Strategic Restructuring to Align Resources with …
Jul 3, 2024 Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile …See details»
Curevac NV Company Profile - Overview - GlobalData
Curevac NV (Curevac) is a biopharmaceutical company that develops new transformative medicines based on messenger ribonucleic acid (mRNA). The company’s pipeline products …See details»
Overview - CureVac
For the first time, through CureVac’s development activities this remarkable molecule started to reveal its huge potential in treating disease to evoke a broad and balanced immune response. …See details»
CureVac Announces Financial Results for the Fourth Quarter and …
Apr 10, 2025 CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision …See details»
CureVac Announces Financial Results for the Fourth Quarter and …
6 days ago "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac. We strategically repositioned the company around impactful R&D …See details»
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 …
Apr 7, 2025 Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary …See details»
Technology - CureVac
Through our proprietary mRNA technology we are able to directly give the body the information it needs to fight disease. Driven by passion for patients, we seek life-altering results for …See details»
Chromosome 1p Loss and 1q Gain for Grading of Meningioma
Apr 3, 2025 ImportanceThe World Health Organization (WHO) classification of central nervous system tumors (CNS) grading for meningioma was updated in 2021 to include rare molecular …See details»